AbbVie Inc. Trade and Non-Trade Receivables Growth

Trade and Non-Trade Receivables Growth of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Trade and Non-Trade Receivables Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Trade and Non-Trade Receivables Growth for the quarter ending March 30, 2021 was 0.51 (a -18.9% decrease compared to previous quarter)
  • Year-over-year quarterly Trade and Non-Trade Receivables Growth decreased by -3.21%
  • Annual Trade and Non-Trade Receivables Growth for 2020 was 0.63 (a -927.12% decrease from previous year)
  • Annual Trade and Non-Trade Receivables Growth for 2019 was -0.08 (a -58.71% decrease from previous year)
  • Annual Trade and Non-Trade Receivables Growth for 2018 was -0.18 (a -135.85% decrease from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Trade and Non-Trade Receivables Growth of AbbVie Inc.

Most recent Trade and Non-Trade Receivables Growthof ABBV including historical data for past 10 years.

Interactive Chart of Trade and Non-Trade Receivables Growth of AbbVie Inc.

AbbVie Inc. Trade and Non-Trade Receivables Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.51
2020 0.63 0.52 0.52 0.12 0.63
2019 0.01 -0.04 -0.05 -0.03 -0.08
2018 0.06 0.18 0.19 0.25 -0.18
2017 0.07 -0.02 -0.04 -0.02 0.51
2016 0.01 0.09 0.16 0.09 0.01
2015 0.27 0.14 0.15 -0.05 0.27
2014 -0.22 0.05 0.01 0.07 -0.22
2013 0.12 0.23 0.25 0.18 0.12
2012 0.13 -0.08 0.13
2011 0.13

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.